Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne (NCT06043102) | Clinical Trial Compass
CompletedNot Applicable
Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne
United States30 participantsStarted 2023-05-16
Plain-language summary
The goal of this clinical trial is to further substantiate the effectiveness and safety of TheraClearX as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults ages 12-40 over the course of 7 weeks. Participants will be asked to have TheraClearX treatments weekly for 6 sessions, attend a follow up appointment 2 weeks after the 6th session, have photos taken of their face and answer questionnaires related to their acne.
Who can participate
Age range
12 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Healthy male or females of all Fitzpatrick Skin Types between 12 and 40 years of age.
. Subjects must be willing to provide verbal understanding and sign an Informed Consent Form, HIPAA Form and Photography Release Form approved by the Institutional Review Board. Subjects less than age of consent must sign an assent for the study and a parent must sign the informed consent (if subject reaches the age of consent during the study they should be re-consented at the next study visit).
. Subjects must be in general good health, as determined by the Investigator.
. Subjects must be willing and able to attend all study visits and comply with the Pre and Post Treatment Instructions.
. Subjects must be willing to have VISIA facial photography imaging of their entire face for overall evaluation of their skin at all Visits.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in inflammatory lesion counts
Timeframe: Baseline to Day 49 or End of Study (EOS) visit
2
Change in non-inflammatory lesion counts
Timeframe: Baseline to Day 49 or End of Study (EOS) visit
3
Percentage/Proportion of subjects who achieve at least a one-grade reduction in the IGA Score
Timeframe: Baseline to Day 49 or End of Study (EOS) visit
. Subjects must be willing and able to complete and understand the various rating questionnaires.
. Subjects must have an IGA score of 2 (mild) or 3 (moderate) at the Baseline Visit.
. Subjects must have a facial acne inflammatory lesion (papules, pustules, and nodules) count with no less than 10 but no more than 50 at the Baseline Visit.
Exclusion criteria
. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, Gram- negative folliculitis, dermatitis, eczema.
. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
. Subjects with more than 50 facial acne inflammatory lesions (papules, pustules, and nodules)
. Subjects with more than 100 facial acne non-inflammatory lesions (open and closed comedones)
. Subjects with more than one (1) facial nodule.
. Subjects with a facial beard or mustache that could interfere with the study assessments.
. Subjects who have a history of experiencing significant burning or stinging when applying any facial treatment (eg, makeup, soap, masks, washes, sunscreens, etc) to their face.